Clinical trials: Hepatic Malignancies
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) participants with moderate and severe…
- Trial name
- NCT05660395
- Testing
- Loncastuximab Tesirine
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 5 people
- Sponsor
- ADC Therapeutics S.A.
BRAF Gene Mutation, Hepatic Complication
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction
This phase I trial studies the side effects and best dose of dabrafenib in treating patients with solid tumors and kidney or liver dysfunction.
- Conditions
- BRAF Gene Mutation, Hepatic Complication, Renal Failure, Solid Neoplasm
- Trial name
- NCT01907802
- Testing
- Dabrafenib, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- 18 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Cholangiocellular Carcinoma
Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
This is a single arm phase II trial of Gemcitabine and Oxaliplatin (Gem-Ox) with Erlotinib (Tarceva) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancer (BTC) patients with platelet counts 100,000/µL.
- Conditions
- Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Bile Duct Cancer
- Trial name
- Gem-ox (NCT00832637)
- Testing
- Cisplatin, Erlotinib, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- New Mexico Cancer Research Alliance
Hepatocellular Carcinoma (HCC)
TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma
This study investigates the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with the immune agent nivolumab compared to TACE alone for treating hepatocellular carcinoma (HCC).
- Trial name
- NCT07053202
- Testing
- Nivolumab, Transarterial Chemoembolization (TACE)
- Where
- China
- Volunteers
- 140 people
- Sponsor
- The First Hospital of Hebei Medical University
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT
This multicenter retrospective study evaluated consecutive patients with large HCC and PVTT who received lenvatinib plus DEB-TACE with/without FOLFOX-HAIC between July 2019 and June 2021.
- Trial name
- NCT06265883
- Testing
- Len+DEB-TACE+HAIC, Len+DEB-TACE
- Where
- China
- Volunteers
- 205 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Colorectal Liver Metastases, Colon Cancer
Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases.
The performance of multiple minor hepatectomies (MMH) instead of major hepatectomies (MH) in patients with colorectal liver metastases (CLM) is object of debate.
- Trial name
- NCT02331641
- Testing
- Hepatectomy
- Volunteers
- 554 people
- Sponsor
- University of Milan
Colorectal Cancer, Colorectal Carcinoma
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Determine the safety of a combination of IFN, celecoxib, and rintatolimod for patients with recurrent colorectal cancer. This will also test whether the above combination can help the immune system to fight the tumors.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Trial name
- NCT01545141
- Testing
- Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Hepatic Neoplasm
Scandinavian Cohort Study for Optimal Use of Portal Vein Embolization
Several aspects on the use of portal vein embolization (PVE) are poorly studied and todays recommendations are based on low-grade evidence.
- Trial name
- NCT04182386
- Testing
- Portal vein embolization
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Karolinska University Hospital
Colorectal Neoplasm, Secondary Malignant Neoplasm of Liver
Comparing Hepatic Intra-arterial Injection of Yttrium-90 Microspheres Versus Fluorouracil (5FU) in Colorectal Cancer Metastatic to the Liver Only
This is a Phase III trial comparing hepatic intra-arterial injection of Yttrium-90 microspheres (selective internal radiation [SIR] spheres) versus infusional intravenous (IV) 5FU in colorectal cancer metastatic to the liver only…
- Trial name
- NCT00199173
- Testing
- SIR Spheres intra-arterial hepatic
- Where
- Belgium
- Sponsor
- Jules Bordet Institute
Hepatic Carcinoma, Chemoembolizaton
Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial).
To evaluate the safety, advantages, and appropriateness of performing transarterial hepatic emobolization of liver cancer via arterial access from the radial artery versus conventional transfemoral arterial access.
- Conditions
- Hepatic Carcinoma, Chemoembolizaton, Transarterial Embolization
- Trial name
- ACCESS (NCT03163186)
- Testing
- Transarterial embolization
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Medical University of South Carolina
Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.
- Conditions
- Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms
- Trial name
- NCT02834780
- Testing
- H3B-6527
- Where
- 44 sites in United States, Belgium and 9 more
- Volunteers
- 128 people
- Sponsor
- H3 Biomedicine Inc.
Colorectal Cancer, Metastatic Cancer
Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy such as floxuridine and irinotecan use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00063960
- Testing
- floxuridine, irinotecan hydrochloride
- Where
- 10 sites in United States
- Volunteers
- 94 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Liver Cancer, Portal Vein Thrombosis
TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis
Therasphere will be administered via catheter through the Hepatic Artery to treat patients with Hepatocellular Carcinoma and Portal vein Thrombosis.
- Trial name
- NCT01556282
- Testing
- TheraSphere
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Emory University
Advanced Adult Primary Liver Cancer
Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE
To investigate the therapy effect and security of oxaliplatin and fluorouracil on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
- Trial name
- NCT02557503
- Testing
- Oxaliplatin and fluorouracil
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhu Xu
Liver Cancer
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as floxuridine and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00410956
- Testing
- bevacizumab, dexamethasone, floxuridine
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
IRE
IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
This is a prospective, randomized, controlled, exploratory Phase II clinical study. Approximately 60 eligible patients with hepatocellular carcinoma and portal vein tumor thrombus who have received three cycles of…
- Trial name
- NCT07799922
- Testing
- IRE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HCC - Hepatocellular Carcinoma
Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus
For HCC patients with PVTT who the researchers believe can benefit from radiotherapy combined with tislelizumab and anlotinib, informed consent forms will be signed, and then they will receive the study treatment and be followed…
- Trial name
- NCT07363512
- Testing
- Radiotherapy combined with tislelizumab and anlotinib
- Volunteers
- 27 people
- Sponsor
- Henan Cancer Hospital
Hepatocellular Carcinoma
Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration
The purposes of this prospective study were to evaluate the successful rate of primary culture of hepatocellular carcinoma cells and cancer-associated fibroblasts from the residual specimens in routine fine-needle aspiration of…
- Trial name
- NCT01549275
- Where
- Taiwan
- Volunteers
- 105 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatocellular Carcinoma, Portal Vein Tumour Thrombosis
Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy
A multicentre, parallel group, randomized controlled Phase II clinical trial evaluating neoadjuvant Atezolizumab/Bevacizumab versus neoadjuvant SBRT in patients with biopsy proven solitary HCC with PVTT involving the portal vein…
- Trial name
- ADVANCE HCC (NCT05137899)
- Testing
- Neoadjuvant
- Where
- 7 sites in Canada
- Volunteers
- 1 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Hepatocellular Carcinoma
HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
The purpose of this prospective, randomized, multicenter, controlled clinical study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared to transarterial chemoembolization (TACE) when…
- Trial name
- NCT07594340
- Testing
- Procedure (FOLFOX-HAIC): Max 4 cycles within first 16 weeks., TACE (transarterial chemoembolization) combined with targeted/immunotherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Binkui Li
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.